Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 12/20 | 0.81 |
| ▸ | PDGFRB | P09619 | 8/20 | 0.81 |
| ▸ | PDGFRA | P16234 | 8/20 | 0.81 |
| ▸ | ABL1 | P00519 | 7/20 | 0.81 |
| ▸ | MAPK14 | Q16539 | 7/20 | 0.81 |
| ▸ | KIT | P10721 | 4/20 | 0.81 |
| ▸ | FGFR1 | P11362 | 11/20 | 0.81 |
| ▸ | WEE1 | P30291 | 5/20 | 0.81 |
| ▸ | EGFR | P00533 | 6/20 | 0.80 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.79 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.79 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.79 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.75 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.75 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.75 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.75 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.75 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2083696 | 0.90 | SRC (1.00) | SRCPDGFRBPDGFRAABL1MAPK14 | |
| SCHEMBL5764062 | 0.90 | FGFR1 (1.00) | SRCPDGFRBPDGFRAABL1MAPK14 | |
| SCHEMBL5762046 | 0.89 | SRC (1.00) | SRCPDGFRBPDGFRAABL1MAPK14 | |
| SCHEMBL1249524 | 0.89 | FGFR1 (1.00) | SRCPDGFRBPDGFRAABL1MAPK14 | |
| SCHEMBL5762600 | 0.89 | FGFR1 (1.00) | SRCPDGFRBPDGFRAABL1MAPK14 | |
| SCHEMBL1334768 | 0.88 | SRC (1.00) | SRCPDGFRBPDGFRAABL1MAPK14 | |
| SCHEMBL2081574 | 0.88 | SRC (1.00) | SRCPDGFRBPDGFRAABL1MAPK14 | |
| SCHEMBL11939526 | 0.88 | FGFR1 (0.84) | SRCPDGFRBPDGFRAABL1MAPK14 | |
| SCHEMBL2083345 | 0.88 | FGFR1 (1.00) | SRCPDGFRBPDGFRAABL1MAPK14 | |
| SCHEMBL6273252 | 0.87 | FGFR1 (0.83) | SRCPDGFRBPDGFRAABL1MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230372496-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | C4 THERAPEUTICS, INC. (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230357180-A1 | DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230279023-A1 | N/O-Linked Degrons and Degronimers for Protein Degradation | C4 THERAPEUTICS, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| US-20230279023-A1 | N/O-Linked Degrons and Degronimers for Protein Degradation | C4 THERAPEUTICS, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| US-20230014124-A1 | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2023-01-19 | — | — | US | disclosed |
| WO-2022081928-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | C4 THERAPEUTICS, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| US-11185592-B2 | Spirocyclic degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-20210106688-A1 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2021-04-15 | — | — | US | disclosed |
| US-10905768-B1 | Heterocyclic degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| US-10849982-B2 | C3-carbon linked glutarimide degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2020-12-01 | — | — | US | disclosed |
| WO-2020132561-A1 | TARGETED PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2020-06-25 | — | — | WO | disclosed |
| US-10660968-B2 | Spirocyclic degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2020-05-26 | — | — | US | disclosed |
| US-20190076542-A1 | C3-CARBON LINKED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 Theraprutics, Inc. (US) | 2019-03-14 | — | — | US | disclosed |
| US-20190076539-A1 | AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 Theraprutics, Inc. (US) | 2019-03-14 | — | — | US | disclosed |
| WO-2017197055-A1 | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2017-11-16 | — | — | WO | disclosed |
| US-20120178180-A1 | METHODS FOR THE IDENTIFICATION OF ZAP-70 INTERACTING MOLECULES AND FOR THE PURIFICATION OF ZAP-70 | CELLZOME GMBH (DE) | 2012-07-12 | — | — | US | disclosed |
| WO-2008110508-A1 | PYRROLO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH INAPPROPRIATE IKK1 ACTIVITY | GLAXO GROUP LIMITED (GB) | 2008-09-18 | — | — | WO | disclosed |
| WO-2008110508-A1 | PYRROLO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH INAPPROPRIATE IKK1 ACTIVITY | GLAXO GROUP LIMITED (GB) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230372496-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | CRBN, CDR2, MDM2 | SRC 959/4885PDGFRB 1440/4885PDGFRA 2052/4885 |
| US-10849982-B2 | C3-carbon linked glutarimide degronimers for target protein degradation | STUB1, UBE3C, UBE3A | SRC 3493/4885PDGFRB 3537/4885PDGFRA 3470/4885 |
| US-20230014124-A1 | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | CRBN, MDM2, STUB1 | SRC 766/4885PDGFRB 2027/4885PDGFRA 2262/4885 |
| US-11185592-B2 | Spirocyclic degronimers for target protein degradation | STUB1, UBE3C, UBE3A | SRC 1396/4885PDGFRB 2146/4885PDGFRA 1886/4885 |
| US-20210106688-A1 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | STUB1, UBE3C, UBE3A | SRC 1396/4885PDGFRB 2146/4885PDGFRA 1886/4885 |
| US-10660968-B2 | Spirocyclic degronimers for target protein degradation | STUB1, UBE3C, UBE3A | SRC 1396/4885PDGFRB 2146/4885PDGFRA 1886/4885 |
| US-10905768-B1 | Heterocyclic degronimers for target protein degradation | CRBN, MDM2, STUB1 | SRC 766/4885PDGFRB 2027/4885PDGFRA 2262/4885 |
| US-20190076539-A1 | AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | GCGR, STUB1, GID4 | SRC 4229/4885PDGFRB 2712/4885PDGFRA 2732/4885 |
| US-20230357180-A1 | DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION | STUB1, MDM2, USP30 | SRC 1460/4885PDGFRB 1950/4885PDGFRA 1356/4885 |
| US-20230279023-A1 | N/O-Linked Degrons and Degronimers for Protein Degradation | CRBN, CBL, STUB1 | SRC 764/4885PDGFRB 3496/4885PDGFRA 3585/4885 |
| US-20190076542-A1 | C3-CARBON LINKED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | STUB1, UBE3C, UBE3A | SRC 3493/4885PDGFRB 3537/4885PDGFRA 3470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.